Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma

Talquetamab is a first-in-class humanized antibody that targets both the G protein-coupled receptor class 5 member D (GPRC5D), a novel orphan receptor on malignant plasma cells, and CD3, a receptor present in T cells.1 This bispecific T-cell engager is currently being used in phase II clinical trials for the treatment of relapsed or refractory (R/R) multiple myeloma (MM). A preliminary report from a phase I clinical trial reported that 75% of treated patients had some skin-related adverse effect (all grade 3/4) with 18% being nail disorders, though there were no treatment discontinuations.